Tominersen
- Generic Name
- Tominersen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1709886-74-7
- Unique Ingredient Identifier
- 7QI41X9QWC
- Associated Conditions
- -
- Associated Therapies
- -
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
Phase 2
Recruiting
- Conditions
- Huntington Disease
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT05686551
- Locations
- 🇺🇸
Uab Medicine, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath